Showing results (161-170 of 252) with videos related to

Sort By:
Pageof 26
Pharmacological Research|December 16, 2021
Current and future therapeutic perspective in chronic heart failureAnnamaria Mascolo, Gabriella di Mauro, Donato Cappetta, et al.
Pharmaceutics|April 28, 2023
The Pharmacological Treatment of Chronic Pain: From Guidelines to Daily Clinical PracticeGianmarco Marcianò, Cristina Vocca, Maurizio Evangelista, et al.
Frontiers in Pharmacology|June 26, 2020
Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance DatabaseRosanna Ruggiero, Federica Fraenza, Cristina Scavone, et al.
Pharmacological Research|March 24, 2023
Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual dataAlessia Zinzi, Mario Gaio, Valerio Liguori, et al.
Frontiers in Drug Safety and Regulation|September 22, 2025
Conducting and interpreting disproportionality analyses derived from spontaneous reporting systemsPaola Maria Cutroneo, Daniele Sartori, Marco Tuccori, et al.
Critical Reviews in Oncology/Hematology|January 22, 2022
The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differencesStefano Fogli, Fabrizio Tabbò, Annalisa Capuano, et al.
Drug Safety|June 19, 2021
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in EudravigilanceAnnamaria Mascolo, Cristina Scavone, Carmen Ferrajolo, et al.
Journal of Clinical Pharmacy and Therapeutics|July 18, 2018
Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting systemMaurizio Sessa, Francesca Futura Bernardi, Andrea Vitale, et al.
British Journal of Pharmacology|April 1, 2015
Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodellingBarbara Rinaldi, Maria Donniacuo, Loredana Sodano, et al.
Frontiers in Pharmacology|November 29, 2023
Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysisAnnamaria Mascolo, Concetta Rafaniello, Gabriella di Mauro, et al.
Pageof 26